2 Predictions for Novo Nordisk in 2026

Novo Nordisk's stock has plunged to near multiyear lows after two years of slowing revenue, multiple downward guidance revisions and U.S. price cuts to semaglutide products (Wegovy/Ozempic), but management expects revenue to stabilize as lower prices drive higher volumes and new indications expand demand. Material 2026 catalysts include an oral semaglutide, Wegovy's approval in MASH (a market where Rezdiffra generated ~$637.3M through 9M 2025) and mid-/late-stage readouts—most notably Amycretin (dual GLP‑1/amylin, subcutaneous and oral) —any of which could help reclaim share lost to Eli Lilly’s Mounjaro; at ~12.7x forward earnings versus a 17.6x healthcare peer average, the shares look attractively valued but remain exposed to competitive and execution risks.

Analysis

Novo Nordisk has traded near multiyear lows after roughly 18 months of weak financial results, multiple downward guidance revisions and clinical setbacks, with revenue growth materially slowed by U.S. government-mandated price cuts to semaglutide products and the company’s own Wegovy price reductions. The article notes these pricing actions will pressure headline growth in 2026 even as management and the author expect stabilization rather than a renewed acceleration.

Downward price moves could be partially offset by higher patient volume and new indications: an oral semaglutide formulation is progressing toward approval and Wegovy’s MASH approval could tap a large unmet-need market where Rezdiffra generated about $637.3 million through the first nine months of 2025. Pipeline catalysts in 2026 include multiple mid- and late-stage readouts, most notably Amycretin (dual GLP‑1/amylin) in subcutaneous and oral forms, which the author says could materially improve efficacy and market competitiveness versus Eli Lilly’s Mounjaro.

Valuation and risk trade-offs are explicit: shares trade at ~12.7x forward earnings versus a 17.6x healthcare peer average, implying upside if execution and readouts are positive, but the company remains exposed to competitive share loss to Eli Lilly and execution/reimbursement risks. Sentiment signals are mildly positive (sentiment_score 0.25, market_impact_score 0.28), consistent with a catalyst-driven recovery scenario rather than a clear, near-term turnaround.

Key Decisions for Investors

• Consider initiating a size-limited position in NVO given a ~12.7x forward P/E and distressed price levels, but cap exposure until 2026 pipeline readouts confirm efficacy or commercial traction
• Use positive mid/late-stage data for Amycretin or regulatory progress on oral semaglutide/MASH uptake as clear add-on triggers, monitor Rezdiffra’s ~$637.3M nine‑month sales as a commercialization benchmark
• Protect downside with hedges or limit sizing because of demonstrated guidance cuts, U.S. pricing/reimbursement risk and competitive share gains by Eli Lilly’s Mounjaro
• Re-evaluate the position within 3–6 months after key readouts and early adoption metrics, and watch Medicare/Medicaid pricing implementation and volume trends as leading indicators of revenue stabilization